Open Orphan PLC (AIM:ORPH) said its Venn Life Sciences drug development consultancy arm has extended its contract with client Carna Biosciences to the end of the year.
The extension is expected to “deliver significant revenue for Venn over the next twelve months”, investors were told.
Venn’s office in Breda, the Netherlands, will provide chemistry, manufacturing and control, non-clinical, clinical and regulatory consultancy services for two of Carna’s development programmes.
"The extension of this contract further demonstrates our ability to collaborate successfully with our clients and provide a service that results in repeat business,” said Open Orphan chairman, Cathal Friel in a statement.
“Venn and Carna have built up a good working relationship over a period of several years where both parties closely collaborated on drug development planning and its execution through consultancy services contracts. We look forward to delivering this contract for Carna in the year ahead."